Circulating biomarkers in the diagnosis and management of hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is one of the most prevalent and lethal causes of cancer-
related death worldwide. The treatment of HCC remains challenging and is largely …
related death worldwide. The treatment of HCC remains challenging and is largely …
[PDF][PDF] Hepatitis B virus DNA levels and outcomes in chronic hepatitis B
Serum hepatitis B virus (HBV) DNA levels can fluctuate markedly during the course of
chronic HBV infection. Both case‐control and cohort studies have shown a significant, dose …
chronic HBV infection. Both case‐control and cohort studies have shown a significant, dose …
[PDF][PDF] Long‐term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B
TT Chang, YF Liaw, SS Wu, E Schiff, KH Han… - …, 2010 - Wiley Online Library
One year of treatment with entecavir (0.5 mg daily) in nucleoside‐naive patients with
hepatitis B e antigen (HBeAg)‐positive or HBeAg‐negative chronic hepatitis B (CHB) …
hepatitis B e antigen (HBeAg)‐positive or HBeAg‐negative chronic hepatitis B (CHB) …
[HTML][HTML] Epidemiology and prevention of hepatitis B virus infection
J Hou, Z Liu, F Gu - International journal of medical sciences, 2005 - ncbi.nlm.nih.gov
Hepatitis B is one of the most common infectious diseases globally. It has been estimated
that there are 350 million chronic hepatitis B virus (HBV) carriers worldwide. The prevalence …
that there are 350 million chronic hepatitis B virus (HBV) carriers worldwide. The prevalence …
Telbivudine versus lamivudine in patients with chronic hepatitis B
Background Reducing hepatitis B virus (HBV) replication to minimal levels is emerging as a
key therapeutic goal for chronic hepatitis B. Methods In this double-blind, phase 3 trial, 1370 …
key therapeutic goal for chronic hepatitis B. Methods In this double-blind, phase 3 trial, 1370 …
[图书][B] Hepatology Principles and Practice: History· Morphology Biochemistry· Diagnostics Clinic· Therapy
E Kuntz - 2006 - Springer
Metabolic processes utilize a variety of differing and contrasting biochemical routes to
enable synthesis of degradation and activation or deactivation of substances; in addition …
enable synthesis of degradation and activation or deactivation of substances; in addition …
Hepatitis B‐related hepatocellular carcinoma: epidemiological characteristics and disease burden
Worldwide, 350 million people are chronically infected with hepatitis B virus (HBV) who are
at greater risk of hepatocellular carcinoma (HCC) compared with uninfected people. The …
at greater risk of hepatocellular carcinoma (HCC) compared with uninfected people. The …
[HTML][HTML] Hepatocellular carcinoma in Egypt: a single center study over a decade
AR El-Zayadi, HM Badran, EMF Barakat… - World journal of …, 2005 - ncbi.nlm.nih.gov
AIM: To identify the trend, possible risk factors and any pattern change of hepatocellular
carcinoma (HCC) in Egypt over a decade. METHODS: All HCC patients attending Cairo …
carcinoma (HCC) in Egypt over a decade. METHODS: All HCC patients attending Cairo …
Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B
Background & Aims: Entecavir demonstrated superior benefit to lamivudine at 48 weeks in
nucleoside-naive patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B …
nucleoside-naive patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B …
Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study
G Chen, W Lin, F Shen, UH Iloeje… - Official journal of the …, 2006 - journals.lww.com
METHODS We measured HBV viral load by real-time polymerase chain reaction on stored
samples from cohort entry (1992–1993) in 2,763 hepatitis B surface antigen (HBsAg) …
samples from cohort entry (1992–1993) in 2,763 hepatitis B surface antigen (HBsAg) …